VSTM
Price:
$3.9
Market Cap:
$173.58M
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 20...[Read more]
Industry
Biotechnology
IPO Date
2012-01-27
Stock Exchange
NASDAQ
Ticker
VSTM
According to Verastem, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.24. This represents a change of -39.63% compared to the average of -2.05 of the last 4 quarters.
The mean historical PE Ratio of Verastem, Inc. over the last ten years is -2.46. The current -1.24 PE Ratio has changed 4.94% with respect to the historical average. Over the past ten years (40 quarters), VSTM's PE Ratio was at its highest in in the September 2020 quarter at 3.90. The PE Ratio was at its lowest in in the June 2021 quarter at -10.35.
Average
-2.46
Median
-1.90
Minimum
-4.82
Maximum
-0.59
Discovering the peaks and valleys of Verastem, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 716.35%
Maximum Annual PE Ratio = -0.59
Minimum Annual Increase = -81.63%
Minimum Annual PE Ratio = -4.82
Year | PE Ratio | Change |
---|---|---|
2023 | -2.05 | 95.89% |
2022 | -1.05 | -76.21% |
2021 | -4.41 | -8.58% |
2020 | -4.82 | 716.35% |
2019 | -0.59 | -81.63% |
2018 | -3.22 | 84.84% |
2017 | -1.74 | 53.03% |
2016 | -1.14 | -1.57% |
2015 | -1.15 | -73.87% |
2014 | -4.42 | -29.57% |
The current PE Ratio of Verastem, Inc. (VSTM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.50
5-year avg
-2.59
10-year avg
-2.46
Verastem, Inc.’s PE Ratio is greater than Viking Therapeutics, Inc. (-47.19), less than Trevena, Inc. (-0.04), less than Karyopharm Therapeutics Inc. (-0.84), less than AcelRx Pharmaceuticals, Inc. (-1.02), less than Infinity Pharmaceuticals, Inc. (-0.02),
Company | PE Ratio | Market cap |
---|---|---|
-47.19 | $4.70B | |
-0.04 | $1.55M | |
-0.84 | $74.58M | |
-1.02 | $14.58M | |
-0.02 | $726.09K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Verastem, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Verastem, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Verastem, Inc.'s PE Ratio?
How is the PE Ratio calculated for Verastem, Inc. (VSTM)?
What is the highest PE Ratio for Verastem, Inc. (VSTM)?
What is the 3-year average PE Ratio for Verastem, Inc. (VSTM)?
What is the 5-year average PE Ratio for Verastem, Inc. (VSTM)?
How does the current PE Ratio for Verastem, Inc. (VSTM) compare to its historical average?